Depleting or pharmacologically inhibiting DRP1 in preclinical breast cancer metastasis models disrupts mitochondrial dynamics, cellular bioenergetics and redox homeostasis, resulting in attenuated brain metastasis (Fig. 7). The gene discussed is DNM1L; the disease is breast cancer.